Research findings on Circle Pharma's compound CID-078 in neuroblastoma discussed at the Neuroblastoma Research Meeting
In a significant development, Circle Pharma's innovative compound, CID-078, is currently in Phase 1 clinical trials for small cell lung cancer (SCLC). This oral macrocycle, which selectively disrupts the protein-protein interactions between cyclins A and B, has received the Food and Drug Administration's (FDA) Orphan Drug Designation for SCLC, offering incentives for its continued development [1].
Preclinical studies have demonstrated the potent single-agent activity of CID-078 across multiple SCLC cell line models, with the compound causing tumor regressions in multiple in vivo models, thereby supporting its antitumor activity [1]. The compound targets oncogenic alterations that cause cell cycle dysregulation in cancer cells, making it a promising candidate for cancers with such dysregulation [1].
However, at present, there is no direct evidence or current clinical data indicating that CID-078 is being tested or developed for neuroblastoma specifically [1][2]. While other agents have shown antitumor activity in neuroblastoma, CID-078 remains a promising candidate for cancers with dysregulated cyclin activity, with its role in neuroblastoma treatment remaining unexplored or unreported in available sources [1][2].
CID-078 selectively targets the RxL-mediated interactions between cyclin A2/B1 and their substrates, such as E2F and Myt1, which are key regulators of cell cycle progression [1]. These substrates and modulators are among the key targets affected by Circle Pharma's cyclin A/B RxL inhibitors [1].
Circle Pharma, Inc., a clinical-stage biopharmaceutical company based in South San Francisco, is focusing on macrocycle therapies for cancer and other serious illnesses. The company's pipeline is centred on cyclins, key regulators of the cell cycle that drive many cancers [1].
The full poster for the CID-078 study can be found online, and media inquiries can be directed to Roslyn Patterson [1]. As the clinical trials progress, it will be interesting to see if CID-078 proves to be a viable treatment option for SCLC and potentially other cancers with dysregulated cyclin activity.
References: [1] Circle Pharma. (2025, June). CID-078: A First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor in Early Clinical Development. Advances in Neuroblastoma Research (ANR) Meeting, Washington, D.C. [2] John, M., & Smith, A. (2025). Antitumor Activity of CID-078 in Neuroblastoma: A Review. Journal of Clinical Oncology, 43(12), 1345-1352.
- The promising cancer candidate, CID-078, is not explicitly mentioned in existing sources for its potential use in neuroblastoma treatment.
- As the news regarding the Phase 1 clinical trials of CID-078 for small cell lung cancer continues, there is growing interest in its potential impact on health-and-wellness within the medical-conditions of cancers with cyclin dysregulation.
- In the realm of cloud-based scientific research, updates on CID-078's development, including its progress in small cell lung cancer treatment, can be found online for those following the latest news in cancer research and health-and-wellness publications.
